Preparing n-of-1 antisense oligonucleotide treatments for rare neurological diseases in Europe: genetic, regulatory, and ethical perspectives

M Synofzik, WMC van Roon-Mom… - nucleic acid …, 2022 - liebertpub.com
Antisense oligonucleotide (ASO) therapies present a promising disease-modifying treatment
approach for rare neurological diseases (RNDs). However, the current focus is on “more …
被引用次数：60 相关文章

Preparing n-of-1 Antisense Oligonucleotide Treatments for Rare Neurological Diseases in Europe: Genetic, Regulatory, and Ethical Perspectives

M Synofzik, WMC van Roon-Mom… - Nucleic acid …, 2022 - pubmed.ncbi.nlm.nih.gov
Antisense oligonucleotide (ASO) therapies present a promising disease-modifying treatment
approach for rare neurological diseases (RNDs). However, the current focus is on" more …

Preparing n-of-1 Antisense Oligonucleotide Treatments for Rare Neurological Diseases in Europe: Genetic, Regulatory, and Ethical Perspectives

M Synofzik, W Roon-Mom… - Nucleic Acid …, 2021 - epub.ub.uni-muenchen.de
Antisense oligonucleotide (ASO) therapies present a promising disease-modifying treatment
approach for rare neurological diseases (RNDs). However, the current focus is on more …
[PDF] universiteitleiden.nl

[PDF][PDF] Preparing n-of-1 Antisense Oligonucleotide Treatments for Rare Neurological Diseases in Europe: Genetic, Regulatory, and Ethical Perspectives

M Synofzik, WMC van Roon-Mom, G Marckmann… - scholarlypublications …
Antisense oligonucleotide (ASO) therapies present a promising disease-modifying treatment
approach for rare neurological diseases (RNDs). However, the current focus is on ''more …
[HTML] nih.gov

[HTML][HTML] Preparing n-of-1 Antisense Oligonucleotide Treatments for Rare Neurological Diseases in Europe: Genetic, Regulatory, and Ethical Perspectives

M Synofzik, WMC van Roon-Mom… - Nucleic Acid …, 2022 - ncbi.nlm.nih.gov
Antisense oligonucleotide (ASO) therapies present a promising disease-modifying treatment
approach for rare neurological diseases (RNDs). However, the current focus is on “more …

[引用][C] Preparing n-of-1 Antisense Oligonucleotide Treatments for Rare Neurological Diseases in Europe: Genetic, Regulatory, and Ethical Perspectives

M Synofzik, V Roon-Mom… - Nucleic Acid …, 2022 - tobias-lib.ub.uni-tuebingen.de
Preparing n-of-1 Antisense Oligonucleotide Treatments for Rare Neurological Diseases in
Europe: Genetic, Regulatory, and Ethical Perspectives Preparing n-of-1 Antisense …

[引用][C] Preparing n-of-1 Antisense Oligonucleotide Treatments for Rare Neurological Diseases in Europe: Genetic, Regulatory, and Ethical Perspectives

M Synofzik, V Roon-Mom, MC Willeke… - Nucleic Acid …, 2022 - ub01.uni-tuebingen.de
Preparing n-of-1 Antisense Oligonucleotide Treatments for Rare Neurological Diseases in
Europe: Genetic, Regulatory, and Ethical Perspectives Preparing n-of-1 Antisense …
[PDF] researchgate.net

[PDF][PDF] Preparing n-of-1 Antisense Oligonucleotide Treatments for Rare Neurological Diseases in Europe: Genetic, Regulatory, and Ethical Perspectives

M Synofzik, WMC van Roon-Mom, G Marckmann… - researchgate.net
Antisense oligonucleotide (ASO) therapies present a promising disease-modifying treatment
approach for rare neurological diseases (RNDs). However, the current focus is on ''more …

Preparing n-of-1 Antisense Oligonucleotide Treatments for Rare Neurological Diseases in Europe: Genetic, Regulatory, and Ethical Perspectives.

M Synofzik, WMC van Roon-Mom… - Nucleic Acid …, 2021 - europepmc.org
Antisense oligonucleotide (ASO) therapies present a promising disease-modifying treatment
approach for rare neurological diseases (RNDs). However, the current focus is on “more …

Preparing n-of-1 antisense oligonucleotide treatments for rare neurological diseases in Europe: genetic, regulatory, and ethical perspectives

M Synofzik… - Nucleic Acid …, 2021 - scholarlypublications …
Antisense oligonucleotide (ASO) therapies present a promising disease-modifying treatment
approach for rare neurological diseases (RNDs). However, the current focus is on" more …